390 related articles for article (PubMed ID: 30621465)
21. Current application status and structure-activity relationship of selective and non-selective JAK inhibitors in diseases.
Li T; Yang X; Zhu J; Liu Y; Jin X; Chen G; Ye L
Int Immunopharmacol; 2023 Sep; 122():110660. PubMed ID: 37478665
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
[TBL] [Abstract][Full Text] [Related]
23. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
24. Advances in the discovery of selective JAK inhibitors.
Menet CJ; Rompaey LV; Geney R
Prog Med Chem; 2013; 52():153-223. PubMed ID: 23384668
[TBL] [Abstract][Full Text] [Related]
25. Design of a peptide inhibitor of tyrosine kinase 2.
Works MG; Song B; Kibler P; Tanga MJ; Galande AK; D'Andrea A
Protein Pept Lett; 2014 May; 21(5):419-25. PubMed ID: 24304386
[TBL] [Abstract][Full Text] [Related]
26. Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides.
Tran NV; Nguyen LTA; Lim KW; Phan AT
Immunohorizons; 2021 Feb; 5(2):70-80. PubMed ID: 33542028
[TBL] [Abstract][Full Text] [Related]
27. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors.
Nogueira M; Puig L; Torres T
Drugs; 2020 Mar; 80(4):341-352. PubMed ID: 32020553
[TBL] [Abstract][Full Text] [Related]
28. Selective JAK inhibitors in development for rheumatoid arthritis.
Norman P
Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
[TBL] [Abstract][Full Text] [Related]
29. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
[TBL] [Abstract][Full Text] [Related]
31. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
[TBL] [Abstract][Full Text] [Related]
32. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Hammitzsch A; Lorenz G; Moog P
Front Immunol; 2020; 11():591176. PubMed ID: 33193430
[TBL] [Abstract][Full Text] [Related]
33. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).
Fensome A; Ambler CM; Arnold E; Banker ME; Brown MF; Chrencik J; Clark JD; Dowty ME; Efremov IV; Flick A; Gerstenberger BS; Gopalsamy A; Hayward MM; Hegen M; Hollingshead BD; Jussif J; Knafels JD; Limburg DC; Lin D; Lin TH; Pierce BS; Saiah E; Sharma R; Symanowicz PT; Telliez JB; Trujillo JI; Vajdos FF; Vincent F; Wan ZK; Xing L; Yang X; Yang X; Zhang L
J Med Chem; 2018 Oct; 61(19):8597-8612. PubMed ID: 30113844
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive assessment of the association between genes on JAK-STAT pathway (IFIH1, TYK2, IL-10) and systemic lupus erythematosus: a meta-analysis.
Yin Q; Wu LC; Zheng L; Han MY; Hu LY; Zhao PP; Bai WY; Zhu XW; Xia JW; Wang XB; Zhang XW; Zheng HF
Arch Dermatol Res; 2018 Nov; 310(9):711-728. PubMed ID: 30171347
[TBL] [Abstract][Full Text] [Related]
35. Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.
Kubo S; Nakayamada S; Tanaka Y
Expert Rev Clin Immunol; 2019 Jul; 15(7):693-700. PubMed ID: 30987474
[No Abstract] [Full Text] [Related]
36. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
Gerstenberger BS; Ambler C; Arnold EP; Banker ME; Brown MF; Clark JD; Dermenci A; Dowty ME; Fensome A; Fish S; Hayward MM; Hegen M; Hollingshead BD; Knafels JD; Lin DW; Lin TH; Owen DR; Saiah E; Sharma R; Vajdos FF; Xing L; Yang X; Yang X; Wright SW
J Med Chem; 2020 Nov; 63(22):13561-13577. PubMed ID: 32787094
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease.
Cui X; Teng Y; Hu Y; Li Q; Pei H; Yang Z
Int Immunopharmacol; 2024 Jan; 126():111238. PubMed ID: 37988912
[TBL] [Abstract][Full Text] [Related]
38. Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis.
Leit S; Greenwood JR; Mondal S; Carriero S; Dahlgren M; Harriman GC; Kennedy-Smith JJ; Kapeller R; Lawson JP; Romero DL; Toms AV; Shelley M; Wester RT; Westlin W; McElwee JJ; Miao W; Edmondson SD; Masse CE
Bioorg Med Chem Lett; 2022 Oct; 73():128891. PubMed ID: 35842205
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum.
Norman P
Expert Opin Ther Pat; 2014 Mar; 24(3):361-8. PubMed ID: 24386992
[TBL] [Abstract][Full Text] [Related]
40. Recent progress on tyrosine kinase 2 JH2 inhibitors.
Deng L; Wan L; Liao T; Wang L; Wang J; Wu X; Shi J
Int Immunopharmacol; 2023 Aug; 121():110434. PubMed ID: 37315371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
